{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:22:58Z","timestamp":1780320178418,"version":"3.54.1"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2021,3]]},"abstract":"Abstract<\/jats:title>\n \n Study Objective<\/jats:title>\n \n Intra\u2010abdominal infections (IAIs) are a common reason for intensive care unit (ICU) admissions, and methicillin\u2010resistant\n Staphylococcus aureus<\/jats:italic>\n (MRSA) is an uncommon pathogen in IAIs. Although more data are available in the setting of non\u2010abdominal sources, there are limited data on the performance of nasal MRSA screening for MRSA IAIs. The primary objective of this study was to evaluate the performance of nasal MRSA screening for MRSA IAIs in critically ill adult patients.\n <\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n This was a multicenter, retrospective, cohort study.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n A 14\u2010hospital healthcare system between January 1, 2014, and August 31, 2019.<\/jats:p>\n <\/jats:sec>\n \n Patients<\/jats:title>\n Adult patients admitted to an ICU for at least 24 h with a diagnosis code for an IAI, a nasal MRSA surveillance screen within 30 days, and an intra\u2010abdominal culture were eligible for inclusion.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n The primary outcome was to evaluate the performance of nasal MRSA screening for MRSA IAIs by calculating the accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).<\/jats:p>\n <\/jats:sec>\n \n Measurements and Main Results<\/jats:title>\n Out of 863 patients randomly screened, a total of 192 patients were included. The study population had a mean age of 60 (SD \u00b115) years, and 101 (53%) patients were male. Six (3.1%) patients were positive for an MRSA IAI, of which four (66.7%) demonstrated a positive nasal MRSA screen. A total of 186 (96.8%) patients were negative for a MRSA IAI, of which 19 (10.2%) were nasal MRSA\u2010positive and 167 (89.8%) were nasal MRSA\u2010negative. Nasal MRSA screening demonstrated the following performance: accuracy 89.1% (95% CI: 83.8%\u201393.1%), sensitivity 66.7% (95% CI: 22.3%\u201395.7%), specificity 89.8% (95% CI: 84.5%\u201393.7%), PPV 17.4% (95% CI: 9.4%\u201330.0%), and NPV 98.8% (95% CI: 96.4%\u201399.6%). There were no significant differences in clinical outcomes, including renal replacement\u2010free days, ICU and hospital length of stay, and in\u2010hospital mortality.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Among critically ill adult patients with IAIs, a negative nasal MRSA screen within 30\u00a0days may help to empirically exclude MRSA as a causative pathogen.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/phar.2497","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T01:53:55Z","timestamp":1608515635000},"page":"257-264","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Performance of nasal methicillin\u2010resistant\n Staphylococcus aureus<\/i>\n screening for intra\u2010abdominal infections in critically ill adult patients"],"prefix":"10.1002","volume":"41","author":[{"given":"Sean","family":"Bennett","sequence":"first","affiliation":[{"name":"Cleveland Clinic Akron General Akron Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanda","family":"Mullen","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Akron General Akron Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavin","family":"Mistry","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Akron General Akron Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5823-7495","authenticated-orcid":false,"given":"Michaelia","family":"Cucci","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Akron General Akron Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-420"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2717"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2004.5.365"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/649554"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2016.261"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.05.013"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0764-7"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1847"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2014.211"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/313454"},{"issue":"2","key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4212\/cjhp.v70i2.1642","article-title":"Nasal\u2010swab results for methicillin\u2010resistant Staphylococcus aureus and associated infections","volume":"70","author":"Rioux J","year":"2017","journal-title":"Can J Hosp Pharm"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz974"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-777X.68531"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2497","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:54:01Z","timestamp":1761065641000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1002\/phar.2497"],"URL":"https:\/\/doi.org\/10.1002\/phar.2497","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]},"assertion":[{"value":"2020-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}